Mario Roselli

Mario Roselli, born in Arezzo on December 16th, 1957 Current position - Head of Medical Oncology, Department of Systems Medicine, University Hospital Tor Vergata, Rome, Italy - Associated Professor in Medical Oncology School of Medicine - Director of the Specialization School in Medical Oncology, University of Rome "Tor Vergata", Rome, Italy Education 1983: M.D. degree (cum laude) State University of Perugia, School of Medicine (Italy) 1986: Ph.D. in Oncology (cum laude) at the II University of Rome "Tor Vergata", Italy 1986-87: Graduate Course “Correlation Between Internal Medicine and Basic Sciences”, Foundation for Advanced Education in The Sciences (FAES), National Institutes of Health, Bethesda, Maryland U.S.A. 1992: Specialty in Nuclear Medicine, University of Naples "Federico II", Naples, Italy Scientific and Academic Career 1986-1990: Fogarty Fellowship at N.I.H., National Cancer Institute, Laboratory of Tumor Immunology and Biology, Bethesda, MD, USA. 1987-1990: Adjunct Professor in "Tumor Immunology" at the School of Oncology, University of Rome "Tor Vergata", Rome, Italy Principal Investigator (PI) and/or Coinvestigator of several clinical projects, sponsored and granted either by the Italian Government Agency (CNR) or by the Italian Ministry of Health for the following years: 1992-97 (Proj. ACRO); 1998-00 (Proj RNAm); 2001-3 (Proj. melanoma); 2001-3 (Proj NSCLC); 2002-4 (Proj breast); 2008 (PRIN). 2004-2008: PI of European Community-sponsored trial titled: “Medical Care Continuity” involving an European oncology network among Italy, Belgium, France and Polland. 1998-present: Member of the Advisory Board of Anticancer Research Institute; Athens, Greece 1992-present: "Consultant Researcher" for Laboratory of Tumor Immunology and Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD, U.S.A. 2009-present: Appointment by EMEA (European Medicines Agency) as a “european expert consultant in oncology” for the SAG (Scientific Advisory Group)-London; UK. 2009-present: Collaboration agreement with the San Raffaele Palliative Care Centres aimed at providing integrated oncologic, medical, and supportive care services for patients with cancer disease and their families, from diagnosis to palliative care, certified by ESMO (European Society of Medical Oncology). 2010-2012: Appointment by AIFA (Italian Drug Agency) as an “expert consultant oncologist” for the National Cancer Table-Rome; Italy. 2015-present: Appointment by University Hospital “Tor Vergata” as a referent for Palliative Cares. 2015- present: Appointment by University Hospital “Tor Vergata” as a referent for Breast Cancer Oncological Network. 2016- present: Director of the School of Specialization in Medical Oncology, at the University of Rome Tor Vergata Research Experience 1. Immunopharmacology of Natural Immunity in vitro and in vivo. Studies on the effects of several drugs on NK activity of mouse lymphocytes against Yac-1 cells, and on tumor cell clearance in mouse organs. 2. Effects on NK activity following Low-dose 8-Interferon + chemotherapy treatment in breast cancer patients. 3. Preclinical and clinical use of monoclonal antibodies as radiopharmaceutical for the detection and therapy of human carcinomas. Use of blood test for detecting the presence of tumor associated antigens. 4. In vivo upregulation of tumor associated antigens (CEA and TAG 72) by administration of biological response modifiers (recombinant "-interferon) in colorectal cancer patients, for the optimization of radioimmunoguided surgery. 5. Immunoscintigraphy and Radioimmunotherapy with 131I-labeled monoclonal antibodies in patients with gastrointestinal cancer. 6. Sentinel lymph node(s) mapping using colloid radiotracers in melanoma and breast cancer patients. 7. Vaccination strategies in patients bearing solid tumors. Prof. Roselli is the President of the Southern Italy Cooperative Oncology Group (SICOG), and member of several national [such as the Italian Society of Immunopharmacology, the Italian Society of Medical Oncology (AIOM), and the Italian Society of Toracic Oncology (AIOT)] and international scientific societies [the European Association for Cancer Research (EACR), the European Society of Medical Oncology (ESMO) and the American Society of Clinical Oncology (ASCO)]. He is also member of the Editorial Boards of several Peer-Reviewed Scientific Journals and has participated as invited speaker and/or chairman to numerous national and international meetings. In collaboration with the BioBIM of the IRCCS San Raffaele Pisana of Rome, he participated in the application of ICT tools in biobank-related research activities. Prof Mario Roselli, so far (January 2017), has coauthored 199 full papers published in peer international journals (Total IF 678; Mean IF: 4.0; h-index 31), 20 book-reviews and 195 abstracts for National as well as International congresses.